{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:39:54Z","timestamp":1793691594932,"version":"4.5.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172910"],"award-info":[{"award-number":["82172910"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972870"],"award-info":[{"award-number":["81972870"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaanxi Innovative Research Team for Key Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular domain (ICD) from the \u03b6 subunit of CD3 as a signaling module, and it is largely unknown how alternative CD3 chains potentially contribute to CAR design. Here, we obtained a series of CAR-T cells against HER2 and mesothelin using a domain comprising a single immunoreceptor tyrosine-based activation motif from different CD3 subunits as the ICD of CARs. While these reconstituted CARs conferred sufficient antigen-specific cytolytic activity on equipped T cells, they elicited low tonic signal, ameliorated the exhaustion and promoted memory differentiation of these cells. Intriguingly, the CD3\u03b5-derived ICD outperformed others in generation of CAR-T cells that produced minimized cytokines. Mechanistically, CD3\u03b5-based CARs displayed a restrained cytomembrane expression on engineered T cells, which was ascribed to endoplasmic reticulum retention mediated by the carboxyl terminal basic residues. The present study demonstrated the applicability of CAR reconstitution using signaling modules from different CD3 subunits, and depicted a novel pattern of CAR expression that reduces cytokine release, thus paving a way for preparation of CAR-T cells displaying improved safety and persistence against diverse tumor antigens.<\/jats:p>","DOI":"10.1038\/s41392-024-02096-5","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T18:01:33Z","timestamp":1736877693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Pengju","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruotong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-1113","authenticated-orcid":false,"given":"Bo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-4672","authenticated-orcid":false,"given":"An-Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-0453","authenticated-orcid":false,"given":"Lintao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for\u2002CAR\u2002T\u2002cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2096_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering\u2002CAR-T\u2002cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"925985","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar, M. P. et al. CAR\u2002T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front. Immunol. 13, 925985 (2022).","journal-title":"Front. Immunol."},{"key":"2096_CR4","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","volume":"26","author":"G Fuc\u00e0","year":"2020","unstructured":"Fuc\u00e0, G. et al. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin. Cancer Res. 26, 2444\u20132451 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of\u2002CAR\u2002T cell-associated\u2002toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2096_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C. et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/imm.13642","volume":"169","author":"X Yin","year":"2023","unstructured":"Yin, X., He, L. & Guo, Z. T-cell\u2002exhaustion\u2002in\u2002CAR-T-cell therapy and strategies to overcome it. Immunology 169, 400\u2013411 (2023).","journal-title":"Immunology"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Tuning charge density of chimeric antigen receptor optimizes\u2002tonic\u2002signaling and\u2002CAR-T\u2002cell fitness. Cell Res 33, 341\u2013354 (2023).","journal-title":"Cell Res"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"2096_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","volume":"116","author":"B Jena","year":"2010","unstructured":"Jena, B., Dotti, G. & Cooper, L. J. Redirecting\u2002T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116, 1035\u20131044 (2010).","journal-title":"Blood"},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava, S. & Riddell, S. R. Engineering\u2002CAR-T\u2002cells: design concepts. Trends Immunol. 36, 494\u2013502 (2015).","journal-title":"Trends Immunol."},{"key":"2096_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K. et al. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2096_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.immuni.2006.01.006","volume":"24","author":"MS Kuhns","year":"2006","unstructured":"Kuhns, M. S., Davis, M. M. & Garcia, K. C. Deconstructing the form and function of the TCR\/CD3 complex. Immunity 24, 133\u2013139 (2006).","journal-title":"Immunity"},{"key":"2096_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.imlet.2014.05.007","volume":"161","author":"A Borroto","year":"2014","unstructured":"Borroto, A., Abia, D. & Alarc\u00f3n, B. Crammed signaling motifs in the T-cell receptor. Immunol. Lett. 161, 113\u2013117 (2014).","journal-title":"Immunol. Lett."},{"key":"2096_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41551-022-00896-0","volume":"6","author":"KS Gordon","year":"2022","unstructured":"Gordon, K. S. et al. Screening for\u2002CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat. Biomed. Eng. 6, 855\u2013866 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2096_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a\u2002JAK-STAT\u2002signaling domain mediates superior anti-tumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"2096_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","volume":"53","author":"W Li","year":"2020","unstructured":"Li, W. et al. Chimeric antigen receptor designed to prevent\u2002ubiquitination\u2002and downregulation showed durable anti-tumor efficacy. Immunity 53, 456\u2013470 (2020).","journal-title":"Immunity"},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","volume":"24","author":"RM Velasco C\u00e1rdenas","year":"2023","unstructured":"Velasco C\u00e1rdenas, R. M. et al. Harnessing CD3 diversity to optimize\u2002CAR\u2002T\u2002cells. Nat. Immunol. 24, 2135\u20132149 (2023).","journal-title":"Nat. Immunol."},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11912-023-01367-8","volume":"25","author":"Q Chu","year":"2023","unstructured":"Chu, Q. Targeting\u2002mesothelin\u2002in solid tumors: anti-mesothelin\u2002antibody and drug conjugates. Curr. Oncol. Rep. 25, 309\u2013323 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"2096_CR21","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1158\/0008-5472.CAN-22-1121","volume":"82","author":"MM Moasser","year":"2022","unstructured":"Moasser, M. M. Inactivating amplified\u2002HER2: challenges, dilemmas, and future directions. Cancer Res 82, 2811\u20132820 (2022).","journal-title":"Cancer Res"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud, G., Lesourne, R. & Love, P. E. Regulatory mechanisms in T cell receptor signalling. Nat. Rev. Immunol. 18, 485\u2013497 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2096_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A. & Maher, J. Strategies to address chimeric antigen receptor tonic signaling. Mol. Cancer Ther. 17, 1795\u20131815 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.omtm.2020.01.012","volume":"16","author":"D Bloemberg","year":"2020","unstructured":"Bloemberg, D. et al. A high-throughput\u2002method\u2002for characterizing novel chimeric\u2002antigen\u2002receptors in Jurkat cells. Mol. Ther. Methods Clin. Dev. 16, 238\u2013254 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2096_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/imcb.12636","volume":"101","author":"C Poloni","year":"2023","unstructured":"Poloni, C. et al. T-cell\u2002activation-induced marker assays in health and disease. Immunol. Cell Biol. 101, 491\u2013503 (2023).","journal-title":"Immunol. Cell Biol."},{"key":"2096_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.trecan.2022.04.004","volume":"8","author":"CC Zebley","year":"2022","unstructured":"Zebley, C. C. & Youngblood, B. Mechanisms of\u2002T\u2002cell exhaustion guiding next-generation immunotherapy. Trends Cancer 8, 726\u2013734 (2022).","journal-title":"Trends Cancer"},{"key":"2096_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","volume":"23","author":"JA Belk","year":"2022","unstructured":"Belk, J. A., Daniel, B. & Satpathy, A. T. Epigenetic regulation of T cell exhaustion. Nat. Immunol. 23, 848\u2013860 (2022).","journal-title":"Nat. Immunol."},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1128\/JVI.79.7.4510-4513.2005","volume":"79","author":"H Unsoeld","year":"2005","unstructured":"Unsoeld, H. & Pircher, H. Complex\u2002memory\u2002T-cell phenotypes revealed by coexpression of\u2002CD62L\u2002and CCR7. J. Virol. 79, 4510\u20134513 (2005).","journal-title":"J. Virol."},{"key":"2096_CR29","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","volume":"184","author":"M Dougan","year":"2021","unstructured":"Dougan, M. et al. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184, 1575\u20131588 (2021).","journal-title":"Cell"},{"key":"2096_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"2096_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41590-023-01444-x","volume":"24","author":"WL Lo","year":"2023","unstructured":"Lo, W. L. et al. A single-amino acid substitution in the adaptor\u2002LAT\u2002accelerates TCR proofreading kinetics and alters\u2002T-cell\u2002selection, maintenance and function. Nat. Immunol. 24, 676\u2013689 (2023).","journal-title":"Nat. Immunol."},{"key":"2096_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu, S. & Karin, M. Regulation and function of\u2002NF-\u03baB\u2002transcription factors in the immune system. Annu. Rev. Immunol. 27, 693\u2013733 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"2096_CR33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0021-9258(17)49904-2","volume":"295","author":"RA Mariuzza","year":"2020","unstructured":"Mariuzza, R. A., Agnihotri, P. & Orban, J. The structural basis of T-cell receptor (TCR) activation: An enduring enigma. J. Biol. Chem. 295, 914\u2013925 (2020).","journal-title":"J. Biol. Chem."},{"key":"2096_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-042617-053429","volume":"36","author":"A Alcover","year":"2018","unstructured":"Alcover, A., Alarc\u00f3n, B. & Di Bartolo, V. Cell biology of T cell receptor expression and regulation. Annu. Rev. Immunol. 36, 103\u2013125 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"2096_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxv060","volume":"28","author":"N Martin-Blanco","year":"2016","unstructured":"Martin-Blanco, N. et al. CD3\u03b5 recruits\u2002Numb\u2002to promote TCR degradation. Int. Immunol. 28, 127\u2013137 (2016).","journal-title":"Int. Immunol."},{"key":"2096_CR36","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.4049\/jimmunol.1203414","volume":"192","author":"A Borroto","year":"2014","unstructured":"Borroto, A. et al. Relevance of Nck-CD3\u03b5 interaction for T cell activation in vivo. J. Immunol. 192, 2042\u20132053 (2014).","journal-title":"J. Immunol."},{"key":"2096_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cell.2008.09.044","volume":"135","author":"C Xu","year":"2008","unstructured":"Xu, C. et al. Regulation of T cell receptor activation by dynamic membrane binding of the CD3\u03b5\u2002cytoplasmic\u2002tyrosine-based\u2002motif. Cell 135, 702\u2013713 (2008).","journal-title":"Cell"},{"key":"2096_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"2096_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. In\u2002vivo\u2002CAR\u2002T\u2002cells move into clinical trials. Nat. Rev. Drug Discov. 23, 727\u2013730 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2096_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder, S. et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40, 53\u201369 (2022).","journal-title":"Cancer Cell"},{"key":"2096_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.it.2003.08.003","volume":"24","author":"LA Pitcher","year":"2003","unstructured":"Pitcher, L. A. & van Oers, N. S. T-cell\u2002receptor\u2002signal\u2002transmission: who gives an\u2002ITAM? Trends Immunol. 24, 554\u2013560 (2003).","journal-title":"Trends Immunol."},{"key":"2096_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.trecan.2021.10.007","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Exploiting T cell signaling to optimize engineered T cell therapies. Trends Cancer 8, 123\u2013134 (2022).","journal-title":"Trends Cancer"},{"key":"2096_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao, X. et al. Mechanisms of\u2002cytokine\u2002release syndrome and neurotoxicity of\u2002CAR\u2002T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40, 367 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2096_CR44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","volume":"182","author":"W Wu","year":"2020","unstructured":"Wu, W. et al. Multiple signaling roles of\u2002CD3\u03b5 and its application in CAR-T cell therapy. Cell 182, 855\u2013871 (2020).","journal-title":"Cell"},{"key":"2096_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1615\/CritRevImmunol.v31.i1.70","volume":"31","author":"VP Dave","year":"2011","unstructured":"Dave, V. P. Role of CD3\u03b5-mediated signaling in T-cell development and function. Crit. Rev. Immunol. 31, 73\u201384 (2011).","journal-title":"Crit. Rev. Immunol."},{"key":"2096_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-020-0732-3","volume":"21","author":"FA Hartl","year":"2020","unstructured":"Hartl, F. A. et al. Noncanonical binding of Lck to CD3\u03b5 promotes TCR signaling and CAR function. Nat. Immunol. 21, 902\u2013913 (2020).","journal-title":"Nat. Immunol."},{"key":"2096_CR47","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1402346","volume":"194","author":"K Watanabe","year":"2015","unstructured":"Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3\u03b6 chimeric antigen receptor-modified effector CD8+ T cells. J. Immunol. 194, 911\u2013920 (2015).","journal-title":"J. Immunol."},{"key":"2096_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715\u2013727 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2096_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.tibtech.2021.12.009","volume":"40","author":"ER Vander Mause","year":"2022","unstructured":"Vander Mause, E. R. et al. Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. Trends Biotechnol. 40, 875\u2013890 (2022).","journal-title":"Trends Biotechnol."},{"key":"2096_CR50","first-page":"E5891","volume":"114","author":"L Li","year":"2017","unstructured":"Li, L. et al. Ionic\u2002CD3-Lck interaction regulates the initiation of T-cell receptor signaling. Proc. Natl Acad. Sci. USA 114, E5891\u2013E5899 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2096_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1126\/science.1152066","volume":"319","author":"T Yeung","year":"2008","unstructured":"Yeung, T. et al. Membrane phosphatidylserine regulates surface charge and\u2002protein\u2002localization. Science 319, 210\u2013213 (2008).","journal-title":"Science"},{"key":"2096_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12000","volume":"250","author":"MS Kuhns","year":"2012","unstructured":"Kuhns, M. S. & Badgandi, H. B. Piecing together the family portrait of TCR-CD3\u2002complexes. Immunol. Rev. 250, 120\u2013143 (2012).","journal-title":"Immunol. Rev."},{"key":"2096_CR53","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong, M., Talluri, S. & Chen, Y. Y. Advances in promoting chimeric antigen receptor T cell trafficking and\u2002infiltration\u2002of solid tumors. Curr. Opin. Biotechnol. 84, 103020 (2023).","journal-title":"Curr. Opin. Biotechnol."},{"key":"2096_CR54","doi-asserted-by":"publisher","first-page":"113796","DOI":"10.1016\/j.celrep.2024.113796","volume":"43","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Suppression of the METTL3-m(6)A-integrin beta1 axis by extracellular acidification impairs T cell\u2002infiltration\u2002and antitumor activity. Cell Rep. 43, 113796 (2024).","journal-title":"Cell Rep."},{"key":"2096_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.biomaterials.2018.06.016","volume":"178","author":"Q Ouyang","year":"2018","unstructured":"Ouyang, Q. et al. Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin. Biomaterials 178, 170\u2013182 (2018).","journal-title":"Biomaterials"},{"key":"2096_CR56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno, J. N. et al. Safety and feasibility of anti-CD19\u2002CAR\u2002T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270\u2013280 (2020).","journal-title":"Nat. Med."},{"key":"2096_CR57","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1073\/pnas.95.2.669","volume":"95","author":"PS Chowdhury","year":"1998","unstructured":"Chowdhury, P. S. et al. Isolation of a high-affinity stable\u2002single-chain\u2002Fv\u2002specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl Acad. Sci. USA 95, 669\u2013674 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2096_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41423-023-01120-y","volume":"21","author":"S Liang","year":"2024","unstructured":"Liang, S. et al. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cell. Mol. Immunol. 21, 213\u2013226 (2024).","journal-title":"Cell. Mol. Immunol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02096-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02096-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02096-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T18:01:37Z","timestamp":1736877697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02096-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-02096-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}